Research and Markets (http://www.researchandmarkets.com/research/eac4ec1b/italy_pharmaceutic) has announced the addition of the "Italy Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.
The pharmaceuticals and healthcare sector will be a target of further cost containment, particularly as National Health System (SSN) data for H111, which shows a decline in spending, highlights the success of previous cost-containment efforts.
Headline Expenditure Projections
- Pharmaceuticals: EUR24.90bn (US$34.63bn) in 2011 to EUR23.52bn (US$31.52bn) in 2012; -5.5% in local currency terms (-9.0% in US dollar terms).
- Healthcare: EUR151.85bn (US$211.19bn) in 2011 to EUR154.02bn (US$206.39bn) in 2012; 1.4% growth in local currency terms (-2.3% in US dollar terms).
- Medical devices: EUR6.42bn (US$8.93bn) in 2011 to EUR6.61bn (US$8.86n) in 2012; 2.9% growth in local currency terms (-0.8% in US dollar terms).
Risk/Reward Rating: In BMI's Pharmaceuticals and Healthcare Risk/Reward (RRRs) for Q212, Italy is eighth out of the 10 markets surveyed in Western Europe. Despite being a large market, Italy is characterised by low levels of annual growth, largely because of widespread price cuts. Additionally, the Italian economy is one of the most vulnerable economies in an already shaky eurozone. High levels of public debt, poor infrastructure and a lack of competitiveness indicate that the country will remain one of the region's laggards over the forecast period.
- Multinational Companies
- Merck & Co
For more information visit http://www.researchandmarkets.com/research/eac4ec1b/italy_pharmaceuticBusiness Wire
Last updated on: 05/04/2012